Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × budigalimab × 30 days × Clear all

NCT06772623 2026-06-04

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Phase 1/2 Recruiting

252 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05005403 2026-05-13

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Phase 1 Recruiting

694 enrolled

BreastGastrointestinalHead & NeckThoracic

Anophthalmia with pulmonary hypoplasia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms